Schering-Plough cleared to acquire Organon BioSciences
Published04 Oct 2007
The Commerce Commission has cleared Schering-Plough Corporation to acquire 100 percent of the shares in, or assets of, Organon Biosciences N.V. The clearance is subject to the divestment undertaking dated 1 October 2007 provided by Schering-Plough Corporation to the Commission pursuant to section 69A of the Commerce Act 1986.
The Commerce Commission has cleared Schering-Plough Corporation to acquire 100 percent of the shares in, or assets of, Organon Biosciences N.V. The clearance is subject to the divestment undertaking dated 1 October 2007 provided by Schering-Plough Corporation to the Commission pursuant to section 69A of the Commerce Act 1986.
Commerce Commission Chair Paula Rebstock said that the Commission was satisfied that the proposed acquisition would not have, or would not be likely to have, the effect of substantially lessening competition in the New Zealand markets for:
intramammary (mastitis) treatments for dry cows;
intramammary (mastitis) treatments for lactating cows;
antimicrobials (antibiotics) for ruminant animals;
prostaglandins (which are used in assisted reproduction);
ectoparasiticides (fly and lice control) for cattle;
ectoparasiticides (fly and lice control) for sheep;
endoparasiticides (worm control) for sheep; and
campylobacter vaccines for sheep.
Schering-Plough is a New Jersey based corporation, listed on the New York Stock Exchange. It is a global science-based healthcare company with activities in the prescription and over-the-counter pharmaceutical, consumer and animal health sectors. In New Zealand, Schering-Plough's animal health business operates as Schering-Plough Coopers. It has one New Zealand company, Schering-Plough Animal Health Limited.
Organon Bioscience is incorporated in the Netherlands. Organon BS is the holding company for the human and animal health activities of Akzo Nobel N.V. Organon BS operates in New Zealand as Organon, the human pharmaceutical business, and Intervet, the animal remedies business.
